vs

Side-by-side financial comparison of New Gold Inc. (NGD) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

New Gold Inc. is the larger business by last-quarter revenue ($44.1M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.).

JB Hi-Fi Limited is an Australian consumer electronics retail company. It is publicly listed on the Australian Securities Exchange. Its headquarters are located in Southbank, Melbourne, Victoria.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NGD vs RXRX — Head-to-Head

Bigger by revenue
NGD
NGD
1.2× larger
NGD
$44.1M
$35.5M
RXRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
NGD
NGD
RXRX
RXRX
Revenue
$44.1M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NGD
NGD
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$44.1M
$5.2M
Q2 25
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
NGD
NGD
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
NGD
NGD
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
NGD
NGD
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
NGD
NGD
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
NGD
NGD
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NGD
NGD
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$1.1B
Total Assets
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NGD
NGD
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
NGD
NGD
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
NGD
NGD
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
NGD
NGD
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
NGD
NGD
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NGD
NGD
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NGD
NGD
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
NGD
NGD
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
NGD
NGD
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
NGD
NGD
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons